Table 2 Clinicopathological characteristics of RCC patients with differential Rad54l2 expression.
From: Estrogen associates with female predominance in Xp11.2 translocation renal cell carcinoma
Characteristic | Low expression of RAD54L2 | High expression of RAD54L2 | p |
|---|---|---|---|
n | 265 | 265 | |
Gender, n (%) | 0.005 | ||
Female | 77 (14.5%) | 109 (20.6%) | |
Male | 188 (35.5%) | 156 (29.4%) | |
Age, n (%) | 0.019 | ||
≤ 60 | 118 (22.3%) | 146 (27.5%) | |
> 60 | 147 (27.7%) | 119 (22.5%) | |
T stage, n (%) | 0.020 | ||
T1 | 118 (22.3%) | 153 (28.9%) | |
T2 | 39 (7.4%) | 30 (5.7%) | |
T3 | 103 (19.4%) | 76 (14.3%) | |
T4 | 5 (0.9%) | 6 (1.1%) | |
N stage, n (%) | 1.000 | ||
N0 | 115 (45.1%) | 124 (48.6%) | |
N1 | 8 (3.1%) | 8 (3.1%) | |
M stage, n (%) | 0.711 | ||
M0 | 208 (41.8%) | 212 (42.6%) | |
M1 | 41 (8.2%) | 37 (7.4%) | |
Pathologic stage, n (%) | 0.011 | ||
Stage I | 115 (21.8%) | 150 (28.5%) | |
Stage II | 30 (5.7%) | 27 (5.1%) | |
Stage III | 75 (14.2%) | 48 (9.1%) | |
Stage IV | 44 (8.3%) | 38 (7.2%) | |
Histologic grade, n (%) | 0.004 | ||
G1 | 2 (0.4%) | 12 (2.3%) | |
G2 | 103 (19.7%) | 124 (23.8%) | |
G3 | 113 (21.6%) | 93 (17.8%) | |
G4 | 44 (8.4%) | 31 (5.9%) |
